Highly active anti-retroviral therapy (HAART) prolongs time to treatment failure in Kaposi's sarcoma

被引:123
作者
Bower, M
Fox, P
Fife, K
Gill, J
Nelson, M
Gazzard, B
机构
[1] Chelsea & Westminster Hosp, Med Day Unit, Dept Oncol, London SW10 9NH, England
[2] Chelsea & Westminister Hosp, Dept HIV Med, London SW10 9NH, England
关键词
Kaposi's sarcoma; highly active antiretroviral therapy;
D O I
10.1097/00002030-199910220-00014
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective: To evaluate the impact of highly active antiretroviral therapy (HAART) on Kaposi's sarcoma. Design: Retrospective study of patients who had received systemic or local treatment for AIDS-related Kaposi's sarcoma who subsequently commenced HAART. Methods: Case note review to determine time to treatment failure for Kaposi's sarcoma before and after starting HAART. Time to treatment failure was calculated from the end of last therapy to the start of the next new treatment for Kaposi's sarcoma. Results: The cohort contained 78 patients. Only 38% had good risk Kaposi's sarcoma (stage T010) at presentation. The median time to treatment failure before starting HAART was 0.5 years. Initial HAART therapy was three or more drugs including a protease inhibitor for 38 (49%), three or more drugs without a protease inhibitor for 27 (35%) and a two-drug protease combination for 13 (16%). The median follow-up after starting HAART was 12 months (range, 0.5-52 months) and anti-Kaposi's sarcoma treatment has been required for 24 (31%) patients. The median time to treatment failure for Kaposi's sarcoma from the start of HAART is 1.7 years. This is statistically longer than the time to treatment failure for the same cohort of patients before they started HAART (log rank chi(2) = 16.5, P < 0.0001). The serum HIV RNA viral load (VL) at the time of Kaposi's sarcoma progression revealed virological failure of HAART (defined as VL > 5000 copies/ml) in 14 of 24 (58%) and good control (VL < 200 copies/ml) in five of 24 (21%). Conclusion: HAART is associated with prolonged time to treatment failure in Kaposi's sarcoma. Progression of Kaposi's sarcoma while on HAART is not necessarily associated with virological failure as determined by rising viral RNA titre.
引用
收藏
页码:2105 / 2111
页数:7
相关论文
共 41 条
[1]  
Aboulafia DM, 1998, MAYO CLIN PROC, V73, P439
[2]   Positive effects of combined antiretroviral therapy on CD4(+) T cell homeostasis and function in advanced HIV disease [J].
Autran, B ;
Carcelain, G ;
Li, TS ;
Blanc, C ;
Mathez, D ;
Tubiana, R ;
Katlama, C ;
Debre, P ;
Leibowitch, J .
SCIENCE, 1997, 277 (5322) :112-116
[3]   KAPOSIS SARCOMA AMONG PERSONS WITH AIDS - A SEXUALLY-TRANSMITTED INFECTION [J].
BERAL, V ;
PETERMAN, TA ;
BERKELMAN, RL ;
JAFFE, HW .
LANCET, 1990, 335 (8682) :123-128
[4]  
BODSWORTH N, 1998, P 12 WORLD AIDS C GE, P317
[5]   KAPOSIS SARCOMA-ASSOCIATED HERPESVIRUS INFECTS ENDOTHELIAL AND SPINDLE CELLS [J].
BOSHOFF, C ;
SCHULZ, TF ;
KENNEDY, MM ;
GRAHAM, AK ;
FISHER, C ;
THOMAS, A ;
MCGEE, JO ;
WEISS, RA ;
OLEARY, JJ .
NATURE MEDICINE, 1995, 1 (12) :1274-1278
[6]   Phase II trial of 13-cis-retinoic acid for poor risk HIV-associated Kaposi's sarcoma [J].
Bower, M ;
Fife, K ;
Landau, D ;
Gracie, F ;
Phillips, RH ;
Gazzard, BG .
INTERNATIONAL JOURNAL OF STD & AIDS, 1997, 8 (08) :518-521
[7]  
Buchbinder SP, 1998, P 2 NAT AIDS MAL C B, pS7
[8]   Resolution of Kaposi's sarcoma associated with undetectable level of human herpesvirus 8 DNA in a patient with AIDS after protease inhibitor therapy [J].
Burdick, AE ;
Carmichael, C ;
Rady, PL ;
Tyring, SK ;
Badiavas, E .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1997, 37 (04) :648-649
[9]  
Centers for Disease Control, 1995, MMWR-MORBID MORTAL W, V44, P849
[10]   IDENTIFICATION OF HERPESVIRUS-LIKE DNA-SEQUENCES IN AIDS-ASSOCIATED KAPOSIS-SARCOMA [J].
CHANG, Y ;
CESARMAN, E ;
PESSIN, MS ;
LEE, F ;
CULPEPPER, J ;
KNOWLES, DM ;
MOORE, PS .
SCIENCE, 1994, 266 (5192) :1865-1869